🇺🇸 FDA
Pipeline program

Alirocumab 150 MG/ML subcutaneous injection

ASAP-SVG, QR#32711/1

Approved small_molecule terminated

Quick answer

Alirocumab 150 MG/ML subcutaneous injection for Saphenous Vein Graft Atherosclerosis is a Approved program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Saphenous Vein Graft Atherosclerosis
Phase
Approved
Modality
small_molecule
Status
terminated

Clinical trials